Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NumeralJSE:XII 19 EV-to-EBITDA is 10.24 as of Aug. 08, 2026, which is 16% below its 10-year median of 12.17. GuruFocus rates JSE:XII with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 739 Drug Manufacturers companies, Numeral ranks better than 59.4% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Numeral's enterprise value is R176.43 Mil.
Numeral's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was R17.23 Mil. Therefore, Numeral's EV-to-EBITDA for today is 10.24.
The historical rank and industry rank for Numeral's EV-to-EBITDA or its related term are showing as below:
JSE:XII'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -130.16 Med: 12.17 Max: 682.55
Current: 10.43
During the past 13 years, the highest EV-to-EBITDA of Numeral was 682.55. The lowest was -130.16. And the median was 12.17.
JSE:XII's EV-to-EBITDA is ranked better than 59.4% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs JSE:XII: 10.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Numeral's share price for today is R0.30.
Numeral's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Numeral's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:XII vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Numeral's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Numeral EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Numeral's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Numeral's EV-to-EBITDA falls into.
Numeral's current Enterprise Value is R176.43 Mil.
Numeral's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R17.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Numeral (JSE:XII) has a EV-to-EBITDA of 10.24 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Numeral. This is 16% below median its historical median of 12.17. According to the industry distribution chart, Numeral ranks #300 out of 739 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Numeral's EV-to-EBITDA too high?
Numeral's current EV-to-EBITDA of 10.24 is 16% below median its 10-year median of 12.17. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Numeral's value of 10.24 is 23.4% below this industry median. Based on the distribution chart, Numeral ranks #300 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Numeral has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Numeral's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Numeral ranks #300 out of 739 companies for EV-to-EBITDA. This puts Numeral in the upper half of its industry. The industry median EV-to-EBITDA is 13.37. Numeral's value of 10.24 is 23.4% below this benchmark. While the company's 10-year median is 12.17 vs. the industry median of 13.37, Numeral has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Numeral's current EV-to-EBITDA of 10.24 is 23.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Numeral. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Numeral's current EV-to-EBITDA is 10.24, which is 16% below median its own 10-year median of 12.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Numeral stock overvalued right now?
Numeral (JSE:XII) has a current EV-to-EBITDA of 10.24. The current EV-to-EBITDA is 10.24, which is 16% below median its 10-year median of 12.17 and 23.4% below the Drug Manufacturers industry median of 13.37. Numeral's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Numeral (JSE:XII), the current EV-to-EBITDA is 10.24 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Numeral Ltd is an investment holding company based in Mauritius with a focus on fintech, biotechnology, and asset management. Geographically it has a presence in countries across Africa, Europe and Asia. The majority of its revenue is generated in the form of Trading income.
19GF Score
Get the complete analysis for JSE:XII
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:XII has been successfully added to your 
